(Q35843864)

English

Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations

scientific article published in August 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1 reference

Europe PubMed Central

Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

venous thromboembolism

1 reference

based on heuristic

inferred from title

author name string

Rosencher N

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

language of work or name

0 references

publication date

1 August 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

59

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

803-810

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Epidural anesthesia and analgesia. Their role in postoperative outcome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Past incidence and future demand for knee arthroplasty in Sweden: a report from the Swedish Knee Arthroplasty Register regarding the effect of past and future population changes on the number of arthroplasties performed

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Interactions of warfarin with drugs and food

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

The effect of anesthetic technique on postoperative outcomes in hip fracture repair.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Spinal anaesthesia and the use of anticoagulants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

European practice guidelines: thromboembolism prophylaxis and regional anesthesia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Spinal and epidural hematoma and low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Statistics: detecting a rare adverse drug reaction using spontaneous reports.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

The pharmacokinetics of fondaparinux sodium in healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2004.03840.X

21 January 2018

Identifiers

10.1111/J.1365-2044.2004.03840.X

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35843864&oldid=1775190848"